Hemogenyx Pharmaceuticals Plc – Director/PDMR Shareholding

7 February 2018

CEO and Co-founder buys shares


Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that on 5 February 2018 Dr Vladislav Sandler, Chief Executive Officer and Co-Founder of the Company, purchased 26,800 ordinary shares of £0.01 in the Company (“Ordinary Shares”) at a price of 2.37 pence per Ordinary Share.


Following this transaction, Dr Sandler now holds 40,478,010 Ordinary Shares, representing approximately 11.37% of the Company’s issued share capital.


The Notification of Dealing Forms provided in accordance with the requirements of MAR in relation to the transactions listed above are set out below:


Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them




Details of the person discharging managerial responsibilities / person closely associated







Vladislav Sandler




Reason for the notification







Chief Executive Officer and Co-Founder


Initial notification /Amendment



Initial notification


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor







Hemogenyx Pharmaceuticals Plc







Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




Description of the financial instrument, type of instrument Ordinary shares of £0.01 each
Identification code ISIN GB00BYX3WZ24


Nature of the transaction



Purchase of Ordinary Shares


Price(s) and volume(s)
Price(s) Volume(s)
2.37p 26,800


Aggregated information
– Aggregated volume  N/A – single transaction
– Price


Date of the transaction



5 February 2018


Place of the transaction



London Stock Exchange





Hemogenyx Pharmaceuticals Limited
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder Via Walbrook PR
Dr Robin Campbell, Chairman
Optiva Securities Ltd Tel: +44 (0)20 3137 1902
Christian Dennis
Shard Capital Partners LLP Tel: +44 (0)20 7186 9950
Damon Heath, Erik Woolgar
Peterhouse Corporate Finance Limited Tel: +44 (0)20 7469 0930
Lucy Williams/Duncan Vasey
Walbrook PR (UK Media & Investor Relations) Tel: +44 (0)20 7933 8780 or
Paul McManus Mob: +44 (0)7980 541 893
US Media enquiries
Lowell Goodman Tel: +1 (323) 646-3249 or


About Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, HemoGenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York.


HemoGenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company’s leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx’s two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care.


For more information, visit


This information is provided by RNS

The company news service from the London Stock Exchange